Pregabalin Capsule
Product Images NDC 0904-7002

22 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 22 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 0904-7002). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pregabalin-equation.jpg (Pregabalin Equation)

Pregabalin-equation.jpg (Pregabalin Equation)
A mathematical formula for estimating creatinine clearance (CLCr) showing variables including age in years, weight in kilograms, serum creatinine in mg/dL, with an adjustment factor for female patients. This formula is typically used in pharmacokinetic calculations related to drug dosing.*
FDA Label Image

Pregabalin-chem-structure.jpg (Pregabalin Chem Structure)

Pregabalin-chem-structure.jpg (Pregabalin Chem Structure)
Chemical structure of pregabalin, the active ingredient in PREGABALIN capsules. The diagram shows the molecular arrangement with functional groups including an amino group and carboxylic acid group.*
FDA Label Image

Pregabalin-fig-01.jpg (Pregabalin Fig 01)

Pregabalin-fig-01.jpg (Pregabalin Fig 01)
A line graph depicting the percent of patients improved versus percent improvement in pain from baseline for Pregabalin capsules at 25 mg, 100 mg, and 200 mg three times a day compared to placebo. The graph shows trends of pain improvement over a range from less than 10% to 100% improvement in pain.*
FDA Label Image

Pregabalin-fig-02.jpg (Pregabalin Fig 02)

Pregabalin-fig-02.jpg (Pregabalin Fig 02)
A Kaplan-Meier plot showing percent improvement in pain from baseline on the x-axis and percent of patients improved on the y-axis. Two curves are displayed, comparing pregabalin 100 mg three times a day versus placebo in terms of patient response over different pain improvement thresholds.*
FDA Label Image

Pregabalin-fig-03.jpg (Pregabalin Fig 03)

Pregabalin-fig-03.jpg (Pregabalin Fig 03)
A line graph showing percent improvement in patients from baseline pain over a range of percent improvements in pain. The graph compares four groups: Pregabalin 300 mg taken two times a day, Pregabalin 150 mg taken two times a day, Pregabalin 75 mg taken two times a day, and placebo. The y-axis is labeled as percent of patients improved, and the x-axis is labeled as percent improvement in pain from baseline.*
FDA Label Image

Pregabalin-fig-04.jpg (Pregabalin Fig 04)

Pregabalin-fig-04.jpg (Pregabalin Fig 04)
A line graph illustrating the percent of patients improved relative to percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, showing trends of patient improvement across different levels of pain improvement.*
FDA Label Image

Pregabalin-fig-05.jpg (Pregabalin Fig 05)

Pregabalin-fig-05.jpg (Pregabalin Fig 05)
A line graph showing the percent improvement in pain from baseline plotted against the percent of patients involved. The graph compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, illustrating different pain improvement rates over the range from 0 to 100 percent.*
FDA Label Image

Pregabalin-fig-06.jpg (Pregabalin Fig 06)

Pregabalin-fig-06.jpg (Pregabalin Fig 06)
A bar chart showing responder rates (%) from two clinical studies (Study E1 and Study E3) comparing placebo and various doses of pregabalin (50 mg/day up to 600 mg/day) including once and thrice daily dosing. The x-axis lists treatment groups, and the y-axis shows responder rates from 0% to 60%. Statistically significant differences from placebo are indicated.*
FDA Label Image

Pregabalin-fig-07.jpg (Pregabalin Fig 07)

Pregabalin-fig-07.jpg (Pregabalin Fig 07)
A line graph showing seizure reduction (median % change from baseline) on the y-axis and dose (mg/day) on the x-axis. The graph compares four studies (E1 BID, E2 TID, E3 BID, E3 TID) with data points indicating significant p-values for dose effects up to 600 mg/day, highlighting seizure reduction response to increasing dose levels.*
FDA Label Image

Pregabalin-fig-08.jpg (Pregabalin Fig 08)

Pregabalin-fig-08.jpg (Pregabalin Fig 08)
A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares three Pregabalin daily doses (300 mg, 450 mg, 600 mg) and placebo. The graph depicts decreasing patient improvement as pain improvement percentage increases along the x-axis.*
FDA Label Image

Pregabalin-fig-09.jpg (Pregabalin Fig 09)

Pregabalin-fig-09.jpg (Pregabalin Fig 09)
A Kaplan-Meier survival curve graph depicting the estimated percentage of subjects without LTR over time in days, comparing Pregabalin and Placebo groups. The y-axis represents the estimated percentage, and the x-axis represents days, with Pregabalin showing a higher percentage of subjects without LTR than Placebo throughout the study period.*
FDA Label Image

Pregabalin-fig-10.jpg (Pregabalin Fig 10)

Pregabalin-fig-10.jpg (Pregabalin Fig 10)
Line graph comparing the percent of subjects improved from baseline to Week 12 for Pregabalin versus placebo. The x-axis represents percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved, with Pregabalin consistently showing higher improvement across the scale compared to placebo.*
FDA Label Image

Pregabalin-fig-11.jpg (Pregabalin Fig 11)

Pregabalin-fig-11.jpg (Pregabalin Fig 11)
A line graph comparing the percent of subjects improved over a range of percent improvement from baseline to Week 16 in a study of Pregabalin versus placebo. The vertical axis represents the percent of subjects improved, and the horizontal axis shows percent improvement from baseline to Week 16 BOCF. Two lines represent Pregabalin (solid) and placebo (dashed), showing greater improvement with Pregabalin over placebo throughout the range.*
FDA Label Image

Pregabalin-fig-12.jpg (Pregabalin Fig 12)

Pregabalin-fig-12.jpg (Pregabalin Fig 12)
A line chart showing the percent of subjects improved from baseline to week 16 using BOCF analysis, comparing Pregabalin versus Placebo. The x-axis represents percent improved from 0 to 100, and the y-axis shows the percent of subjects improved, ranging from 0 to 100 percent. Two lines depict outcomes for Pregabalin (solid) and Placebo (dashed), illustrating greater improvement rates for Pregabalin over Placebo.*
FDA Label Image

25mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 07)

25mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 07)
PREGABALIN 25 mg Capsules unit dose label from Major Pharmaceuticals. The label displays the NDC 0904-6991-61 and specifies 100 capsules (10 x 10) in the package. It includes usage instructions for pharmacists, storage conditions, safety warnings, and manufacturer information from Major Pharmaceuticals, Indianapolis, IN.*
FDA Label Image

50mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 06)

50mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 06)
Major Pharmaceuticals Pregabalin 50 mg oral capsules unit dose packaging label. The label shows the product name, dosage strength (50 mg), form (capsules), quantity (100 capsules, 10 packs of 10), NDC 0904-6992-61, and indicates Rx only. It includes storage instructions, pharmacological contents, institutional use warning, and distributor information from Major Pharmaceuticals in Indianapolis, IN.*
FDA Label Image

75mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 05)

75mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 05)
Packaging label for Major Pharmaceuticals Pregabalin Capsules, 75 mg strength. This unit dose package contains 100 capsules (10 x 10). The label includes dosage information, storage instructions, and warnings, and specifies that the product is Rx only. The label features the Major Pharmaceuticals logo and a barcode at the bottom.*
FDA Label Image

100mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 04)

100mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 04)
Packaging label of Pregabalin Capsules 100 mg by Major Pharmaceuticals. The label shows the product name Pregabalin Capsules with strength 100 mg and quantity of 100 capsules (10 x 10) in unit dose packaging. It includes instructions for pharmacists to dispense with a medication guide, storage information, and safety warnings. The label also displays the National Drug Code (NDC) 0904-7001-61 and details about packaging and distribution by Major Pharmaceuticals in Indianapolis, IN.*
FDA Label Image

150mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 03)

150mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 03)
Package label for Pregabalin Capsules 150 mg by Major Pharmaceuticals. The unit dose packaging contains 100 capsules (10 x 10). The label includes NDC 0904-7002-61 and states it is Rx only. Additional details include dosage per capsule and storage instructions, highlighting that this package is not for individual use but for institutional use only.*
FDA Label Image

200mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 02)

200mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 02)
Package label for Pregabalin Capsules 200 mg by Major Pharmaceuticals. The label includes NDC 0904-7003-04, indicates a unit dose package with 30 capsules (3 x 10), and states 'Rx only.' It features storage instructions, warnings, and distributor information from Major Pharmaceuticals, Indianapolis, IN.*
FDA Label Image

225mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 01)

225mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 01)
This image shows the front and back unit dose labels of Major Pharmaceuticals' Pregabalin Capsules, 225 mg strength. The label indicates dispensing with medication guide, packaging of 30 capsules (3 x 10), and Rx only status. Storage and handling instructions, cautionary statements, and distributor details are included on the back label.*
FDA Label Image

300mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 00)

300mg Carton Label (7a3d7f07 64b3 4a56 825b 51b327b65e68 00)
PREGABALIN 300 mg capsules unit dose label from Major Pharmaceuticals. The label includes the NDC 0904-7005-04 and states the package contains 30 capsules (3 x 10). It highlights prescription status (Rx only) and pharmacist instructions for dispensing with medication guide. Storage conditions and warnings about child resistance and institutional use are also noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.